NAME: Daniel R. Couriel

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Professor of Internal Medicine, School of Medicine, University of Utah

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

1. Personal Statement

I am a hematologist/oncologist and the Director of the Utah Blood and Marrow Transplant Program in the Division of Hematology and Hematologic Malignancies, at Huntsman Cancer Institute, University of Utah. I am a tenure-track Professor and hold the Huntsman Cancer Institute Endowed Professorship in Adult Leukemia Research. My area of research has focused on the diagnosis, prevention and innovative therapies for both acute and chronic graft-versus-host disease (GVHD), the main complication of hematopoietic stem cell transplantation. My clinical research career started in 1999 at the University of Texas MD Anderson Cancer Center, continued at the University of Michigan and now in my current position. I have pioneered different therapies for GVHD, including TNF alpha inhibition with infliximab, MTOR inhibition with sirolimus, and extracorporeal photopheresis (ECP). In the last several years, I have also concentrated on different aspects of the impact of chronic GVHD on HSCT survivors, an area that has motivated me to establish Chronic GVHD Programs that functioned as multidisciplinary clinics with people that had an interest and expertise in caring for these patients. The world of HSCT is small enough that enables frequent at fruitful interactions with colleagues in meetings and committees. For that reason, I have served as a co-Chair for the GVHD subcommittee in the Center for International Blood and Marrow Transplant Research (2014-2018), and also the Ancillary and Supportive Care Subcommittee of the NIH Consensus Group for Clinical Trials in chronic GVHD (2004, 2014). I am also faculty in the American Society of Blood and Marrow Transplantation Clinical Research Training Course. Finally, I enjoy being part of the constantly improving quality management area in HSCT, and I am on the Board of Directors for the Foundation for Accreditation of Cellular Therapy (FACT), where I have served as an inspector and on several different committees for the last several years. I also take great pride in being a conscientious mentor. In the past ten years I have mentored four fellows, all of whom are still in research careers, and I am currently mentoring three junior faculty. I look forward to mentoring junior faculty in the HCI DOCS program.

Ongoing and recently completed projects that I would like to highlight include:

#13-PAF03850

Couriel (PI)                                                                                                                                                                                                                 

06/01/13-04/01/21

Scleroderma Foundation/Fred Hutchinson Cancer Research Center
(UMCC 2012.107) A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of Systemic Sclerosis

Role: Principal Investigator

Couriel (PI)                                                                                           

07/01/15-10/31/20

ADIENNE Pharma & Biotech

Adn011

Role: Principal Investigator

Couriel (PI)                                                                                           

04/01/14-03/01/19

Therakos, Inc.

14-PAF03471
A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) versus Corticosteroids in the Treatment of Patients with Secondary Progressive Multiple Sclerosis (SPMS)

Role: Principal Investigator

Couriel (PI)                                                                                           

12/01/13-11/01/18

Polyphor Ltd

14-PAF01398
A Phase I/II Study Evaluating the Efficacy and Safety of POL 6326 for Mobilization and Transplantation of HLA-Matched Sibling Donors in Patients with Advanced Hematologic Malignancies

Role: Principal Investigator

Positions and Scientific Appointments

2020-                                                   Board Liaison position for the ASTCT Committee on International Affairs

2020-                                       Committee Board Member, ASTCT Membership Committee

2020-                                       Member, ASTCT Committee on Membership and Inclusion

2020                      Member, Treatment of Established Chronic GVHD Subcommittee, NIH Consensus Project for Clinical Trials in Chronic GVHD

2019-                     Director at Large, Board of Directors, American Society of Transplantation and Cellular Therapy (ASTCT)

2019                      Member, Hematopoietic Stem Cell Transplantation Guidelines and Chair, Acute GVHD Sub committee, National Comprehensive Cancer Network (NCCN)

2018-                                       Board of Directors, Foundation for Accreditation of Cellular Therapy

2015-                     Director, Blood and Marrow Transplant Program, Huntsman Cancer Institute, Salt Lake City, UT

2015-                                        Professor of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT

2015-2019                   Committee Member, Conquer Cancer Foundation. ASCO

2013-                      Co-Chair, Center for International Blood and Marrow Transplant Research. Graft Versus Host Disease subcommittee

2013-                      Co-Chair, National Institutes of Health. Ancillary and Supportive Care of Chronic Graft Versus Host Disease (GvHD), NIH Consensus Project

2012-2015              Program Director, Adult Blood and Marrow Transplantation Clinical Program, University of   Michigan Comprehensive Cancer Center, Ann Arbor, MI

2010-2015              Clinical Professor, Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI

2010-2012              Clinical Director, Adult Blood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

2007-2010              Director, Allogeneic Transplant Program and Stem Cell Collection, TriStar Sarah Cannon Center for Blood Cancers, Nashville, TN

2005-2007              Associate Professor of Medicine, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX

2004-2007              Attending Physician, Apheresis Center, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX

1999-2005              Assistant Professor of Medicine, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX

1997-1999              Assistant Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL

1995-1996              Guest Researcher, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD

1994-1995              Attending Physician, Hematology and Bone Marrow, Transplant Units, Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD

1992-1993                    Instructor, Department of Medicine, Tufts University School of Medicine, Boston, MA

1988-1989                    Instructor, Pharmacology, University of Buenos Aires School of Medicine, Buenos Aires

1984-1986                    Instructor, Biochemistry, University of Buenos Aires School of Medicine, Buenos Aires

Honors

2016                       Huntsman Cancer Institute Endowed Professorship in Adult Leukemia Research, University of Utah, Salt Lake City, UT

2012                                         Division of Hematology/Oncology Chief’s Award, University of Michigan, Ann Arbor, MI

1991                       House Staff Scientific Award, St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA

1987                      Graduated Cum Laude, University of Buenos Aires School of Medicine, Buenos Aries, Argentina

1. In this set of early publications we concentrated on understanding complications related to conditioning regimens and graft-versus-host disease (GVHD) that have a major impact on non-relapse mortality after blood and marrow transplantation. 
   1. Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett AJ (1996). Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant, 18(2), 347-53.
   2. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R (2004). Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant, 10(3), 178-85.
   3. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS (2004). Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood, 104(3), 857-64.
   4. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qazilbash MH, Champlin RE, Couriel DR (2007). Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood, 109(7), 2751-8.
2. My earlier publications are focused on novel therapies for both acute and chronic graft-versus-host disease. Most agents in the studies listed in this section are now broadly utilized in clinical practice. 
   1. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R (2004). Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood, 104(3), 649-54.
   2. Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C, Hicks K, Donato M, Giralt S, Khouri IF, Hosing C, de Lima MJ, Andersson B, Neumann J, Champlin R (2005). Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol, 130(3), 409-17.
   3. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A (2009). A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant, 15(12), 1555-62. PMCID: PMC4114035
   4. Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ (2011). Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol, 29(3), 294-302. PMCID: PMC3056464
3. The publications listed in this section address the main long term complication of blood and marrow transplantation survivors. This section includes the part of my work geared towards improving the understanding of this very complex disease. 
   1. Smith SR, Haig AJ, Couriel DR (2015). Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease. [Review]. Biol Blood Marrow Transplant, 21(5), 799-808.
   2. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringden OT, Savani BN, Socie G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Perez-Simon JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhauser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ (2015). Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant, 21(2), 266-74. PMCID: PMC4326247
   3. Abedin S, Yanik GA, Braun T, Pawarode A, Magenau J, Goldstein SC, Levine JE, Kitko CL, Couriel DR (2015). Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. Biol Blood Marrow Transplant, 21(6), 1127-31.
   4. Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, Hoodin F, Johnston L, Lawitschka A, McDonald GB, Opipari AW, Savani BN, Schultz KR, Smith SR, Syrjala KL, Treister N, Vogelsang GB, Williams KM, Pavletic SZ, Martin PJ, Lee SJ, Couriel DR (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant, United States, 21(7), 1167-87.
4. This section summarizes my research interest in extracorporeal photophoresis as a treatment modality for chronic GVHD. I included the earlier work, which includes the earliest major publication in this topic, and more recent insights into the mechanism of action. 
   1. Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, Forman AD, Kumar AJ, Champlin R, Couriel D (2003). Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol, 122(1), 128-34.
   2. Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, Donato M, Champlin R (2006). Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant, 12(1 Suppl 2), 37-40.
   3. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M (2006). Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood, 107(8), 3074-80.
   4. Zhu L, Couriel DR, Chang CH (2015). The effect of extracorporeal photopheresis on T cell response in chronic graft-versus-host disease. Leuk Lymphoma, 1-9.
5. Although my research has focused mostly on graft-versus-host disease, I have also participated in the evaluation of outcomes of blood and marrow transplantation in different settings and diseases.
   1. Abedin S, Peres E, Levine JE, Choi S, Yanik G, Couriel DR (2014). Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation. Biol Blood Marrow Transplant, 20(12), 2062-6. PMCID: PMC4291068
   2. Magenau JM, Braun T, Reddy P, Parkin B, Pawarode A, Mineishi S, Choi S, Levine J, Li Y, Yanik G, Kitko C, Churay T, Frame D, Riwes MM, Harris A, Bixby D, Couriel DR, Goldstein SC (2015). Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol, 94(6), 1033-41.
   3. Caram MV, Bellile EL, Englesbe MJ, Terjimanian M, Wang SC, Griggs JJ, Couriel D (2015). Sarcopenia is associated with autologous transplant-related outcomes in patients with lymphoma. Leuk Lymphoma, 1-8.
   4. Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR (2016). Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Biol Blood Marrow Transplant, 22(1), 54-60.